undamentalytics Newsletter
Sign in

Protagonist Therapeutics, Inc income statement

In fiscal 2025, Protagonist Therapeutics, Inc reported revenue of $46.0m, down 89.4% on the year before, operating income of −$158m (a -343.6% margin) and net income of −$130m, or −$2.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue203102927276043446282
Research and development46596575126126120138159175
General and administrative12141619273233434548
Operating income−38−42−81−65−126−131−94253−15858
Interest expense——01——————
Income before tax−37−40−78−65−126−127−79279−12984
Income tax0−1−11000411
Net income−37−39−77−66−126−127−79275−13083
Diluted EPS−$2.09−$1.74−$2.98−$1.92−$2.71−$2.60−$1.39$4.23−$2.05$1.23
Diluted shares (average)18m22m26m34m46m49m57m65m64m67m
EBITDA−37−42−80−64−125−130−93254−15760

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PHAT vs PTGXPTGX vs SNDXPTGX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Protagonist Therapeutics, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Protagonist Therapeutics, Inc.